Login to Your Account



A Blockbuster's Days May be Numbered

Head to Head, GA101 Trumps Rituxan in Chronic Lymphocytic Leukemia

By Marie Powers
Staff Writer

Wednesday, July 24, 2013
in_the_clinic.jpg

Genentech Inc., a unit of the Roche Group, received the confirmation on lead hematology candidate GA101 (obinutuzumab) it's been awaiting since an interim analysis at the end of January showed marked improvement in progression-free survival (PFS) in a Phase III trial in previously untreated chronic lymphocytic leukemia (CLL).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription